المؤلفون: Gordon, Leo, Karmali, Reem, Kaplan, Jason, Popat, Rakesh, Burris, Howard A. III, Ferrari, Silvia, Carpio Segura, Cecilia Carmen, Bosch Albareda, Francesc

المساهمون: Institut Català de la Salut, Gordon LI, Karmali R, Kaplan JB Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Popat R Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK. Burris HA 3rd Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA. Ferrari S Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy. Carpio C Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Sang - Malalties - Tractament, Cèl·lules B - Tumors - Tractament, Proteïnes quinases - Inhibidors - Ús terapèutic, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, Other subheadings::Other subheadings::/therapeutic use, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas, Otros calificadores::Otros calificadores::/uso terapéutico, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas

وصف الملف: application/pdf

العلاقة: Oncotarget;14; https://doi.org/10.18632/oncotarget.28352Test; Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, et al. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 Jan 26;14:57–70.; https://hdl.handle.net/11351/9094Test

الإتاحة: https://doi.org/10.18632/oncotarget.28352Test
https://hdl.handle.net/11351/9094Test

المؤلفون: Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A., III

المساهمون: Medicine, School of Medicine

المصدر: PMC

مصطلحات موضوعية: Urological cancer, Cancer therapy, Gynaecological cancer

وصف الملف: application/pdf

العلاقة: British Journal of Cancer; Voss MH, Gordon MS, Mita M, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020;123(11):1590-1598. doi:10.1038/s41416-020-01041-x; https://hdl.handle.net/1805/28734Test

الإتاحة: https://doi.org/10.1038/s41416-020-01041-xTest
https://hdl.handle.net/1805/28734Test

المؤلفون: Dummer, Reinhard, Sandhu, Shahneen Kaur, Miller, Wilson H., Butler, Marcus O., Blank, Christian U., Munoz-Couselo, Eva, Burris, Howard A., III, Postow, Michael A., Chmielowski, Bartosz, Middleton, Mark R., Berking, Carola, Hassel, Jessica Cecile, Gesierich, Anja, Mauch, Cornelia, Kleha, Joseph, Gollerkeri, Ashwin, Harney, Allison, Pickard, Michael D., Ascierto, Paolo Antonio

مصطلحات موضوعية: ddc:no

العلاقة: Dummer, Reinhard, Sandhu, Shahneen Kaur, Miller, Wilson H., Butler, Marcus O., Blank, Christian U., Munoz-Couselo, Eva, Burris, Howard A., III, Postow, Michael A., Chmielowski, Bartosz, Middleton, Mark R., Berking, Carola, Hassel, Jessica Cecile, Gesierich, Anja, Mauch, Cornelia, Kleha, Joseph, Gollerkeri, Ashwin, Harney, Allison, Pickard, Michael D. and Ascierto, Paolo Antonio (2020). A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

الإتاحة: https://kups.ub.uni-koeln.de/33320Test/

المؤلفون: Bendell, Johanna C., Meluch, Anthony, Peyton, James, Rubin, Mark, Waterhouse, David, Webb, Charles, Burris, Howard A. III, Hainsworth, John D.

المصدر: Clinical Advances in Hematology & Oncology; Jul2012, Vol. 10 Issue 7, p430-437, 8p